A physician-supervised metabolic health and longevity programme — not a quick-fix. GLP-1 therapy where clinically indicated (Mounjaro, Ozempic, Wegovy, generic semaglutide), Indian BMI thresholds, full metabolic screening, four pillars (medical evaluation, nutrition, exercise, skin preservation). Directed by Dr. Rejeesh Menon, MD Internal Medicine, US-licensed. Open at DermaVue Kochi, 100m from Pulinchode Metro.
DermaVue Kochi SuperHuman is a physician-supervised medical weight loss programme, framed as metabolic health and longevity, not cosmetic weight loss. Eligibility uses Indian BMI thresholds (≥25 for obesity, ≥23 with metabolic comorbidity). GLP-1 receptor agonist therapy (Mounjaro/tirzepatide, Ozempic/Wegovy/semaglutide, generic semaglutide post-2026) is prescribed where clinically indicated after full metabolic screening. Four pillars: medical evaluation, Kerala-adapted nutrition, structured exercise, skin preservation (Ozempic-face prevention). Programme runs 12-18 months with planned maintenance phase. Directed by Dr. Rejeesh Menon (MD Internal Medicine, US-licensed, WSU faculty, ACP Fellow). From ₹300 consultation + ₹8,000/month programme entry (medications additional, depending on prescription).
Sustainable fat loss is one outcome. Metabolic markers, muscle preservation, cardiovascular risk reduction, and skin quality matter equally, and the four pillars are designed against that.
Initial physician consultation. Full metabolic screening, HbA1c, fasting insulin, lipid panel, liver enzymes, thyroid panel, vitamin D, body composition. Eligibility against Indian BMI thresholds (NOT WHO Western thresholds). Individualised protocol, not a template.
Dietary plan emphasising protein density, fibre, and traditional Malayali ingredients. The programme works with Kerala food culture, not against it, appam, kappa, fish, coconut all stay (in adjusted portion structures). PCOS / insulin-resistance adaptations where indicated.
Resistance training to preserve muscle during fat loss (the single biggest factor in metabolic-rate preservation), HIIT for VO₂ max, zone-2 cardio for mitochondrial density. Programme adapted to the patient's starting fitness, not a punitive boot-camp.
Rapid GLP-1-induced fat loss can cause "Ozempic face", visible facial-volume depletion. DermaVue handles this proactively: structured dose titration to avoid sudden loss, timely HA dermal-filler restoration, skin booster injections. Doing both at one clinic is the operational advantage.
South Asian metabolism develops insulin resistance and visceral adiposity at lower BMI than European populations. Indian Council of Medical Research (ICMR) and the Research Society for the Study of Diabetes in India (RSSDI) define overweight and obesity accordingly.
| Marker | Indian threshold | WHO Western |
|---|---|---|
| Overweight | BMI ≥ 23 kg/m² | BMI ≥ 25 kg/m² |
| Obesity | BMI ≥ 25 kg/m² | BMI ≥ 30 kg/m² |
| Abdominal obesity · women | Waist > 80 cm | Waist > 88 cm |
| Abdominal obesity · men | Waist > 90 cm | Waist > 102 cm |
SuperHuman programme eligibility: BMI ≥ 25, OR BMI ≥ 23 with metabolic comorbidity (T2DM, pre-diabetes, hypertension, fatty liver, PCOS).
Dual GLP-1 + GIP agonist. Highest mean weight loss in head-to-head trials. Brand. From ₹13,125/month dose-dependent.
GLP-1 monoagonist. Most clinical data + longest safety record. Brand. Dose-dependent.
Post-March 2026 from Sun Pharma, Zydus, Dr. Reddy. Bioequivalent to brand. From ₹325/week.
Selection is physician-led based on metabolic profile, tolerance, cost preference, and clinical history, not patient-self-selected.
Published trial data on GLP-1 monotherapy (no exercise structure) shows roughly 25-40% of total weight lost is lean muscle mass, not just fat. That depresses resting metabolic rate, reduces strength, and accelerates the post-discontinuation regain pattern. The SuperHuman exercise pillar is non-negotiable: structured resistance training preserves muscle, protects metabolism, and protects the post-programme result.
HIIT raises VO₂ max (the single strongest cardiovascular longevity marker). Zone-2 cardio builds mitochondrial density. The combination, resistance + HIIT + zone-2, is the longevity programme structure, not the punishment-cardio many parlour-style "weight loss" programmes default to.
Dr. Rejeesh Menon directs the SuperHuman metabolic health and longevity programme across the DermaVue network. He is a US-trained internist (the appropriate specialty for GLP-1 weight management), Washington State University faculty, and ACP Fellow. Internal-medicine training is what these medications require, they are not aesthetic drugs and should not be prescribed casually. At the Kochi clinic, branch physicians handle monthly follow-up reviews and the skin-preservation pillar is led by Dr. Minu Liz Mathew (MD DVL), with the rest of the 5-doctor dermatology team available for the aesthetic side.
Initial physician consultation (₹300). Full metabolic blood panel. Body composition. History review for contraindications. Eligibility decision before any prescription.
Individual protocol, medication class, starting dose, nutrition plan, exercise programme, skin-preservation baseline. Written plan with milestones.
Structured dose escalation with weekly WhatsApp check-ins. Side-effect management. First HbA1c review at month 3.
Monthly in-person reviews. Quarterly metabolic panels. Proactive skin-preservation work as fat loss accelerates. Exercise progression.
Structured tapering. Lower-dose maintenance medication where clinically appropriate. Ongoing nutrition and resistance training. Quarterly metabolic reviews.
SuperHuman patients aren't walk-in distance from our Kochi clinic. Monthly reviews are designed around the Greater Cochin commute, including Sunday slots (11 AM-5 PM) most workable for corporate professionals.
Medical weight loss at DermaVue Kochi is a physician-supervised metabolic health and longevity programme, not a cosmetic or quick-fix intervention. The SuperHuman programme combines metabolic screening (HbA1c, fasting insulin, lipid panel, thyroid, liver), GLP-1 receptor agonist therapy where clinically indicated (Mounjaro/tirzepatide, Ozempic/Wegovy/semaglutide, generic semaglutide), Kerala-adapted nutrition, structured exercise, and skin-preservation protocols (Ozempic-face prevention). Programme runs 12-18 months with planned maintenance phase. Led by Dr. Rejeesh Menon (MD Internal Medicine, US-licensed, WSU faculty).
Eligibility is assessed against Indian BMI thresholds (NOT WHO Western thresholds): BMI ≥ 25 kg/m² (Indian obesity threshold) OR BMI ≥ 23 kg/m² with metabolic comorbidity (type 2 diabetes, pre-diabetes, hypertension, fatty liver, PCOS) OR waist circumference > 90 cm (men) / > 80 cm (women). Initial physician evaluation determines candidacy after full metabolic screening, not every patient is right for GLP-1 therapy.
Where clinically indicated and after eligibility screening: Mounjaro (tirzepatide), Ozempic and Wegovy (semaglutide injectable), and generic semaglutide (post-March 2026 from Sun Pharma, Zydus, Dr. Reddy). Programme entry from ₹8,000/month; Mounjaro/Tirzepatide dose-dependent from ₹13,125/month; generic semaglutide from ₹325/week. Dose titration follows a structured protocol with monthly physician review.
Sustainable fat loss is one outcome, but the programme primarily targets metabolic health markers (HbA1c, fasting insulin, lipid profile, liver enzymes, blood pressure) and longevity indicators (visceral fat, sarcopenic muscle preservation, cardiovascular risk). Weight loss without metabolic and muscle preservation is a poor outcome, and the four pillars (medical evaluation, nutrition, exercise, skin preservation) are designed against that.
1) Medical evaluation, initial physician consultation, full metabolic blood panel, individualised eligibility and protocol. 2) Nutrition, Kerala-adapted dietary plan emphasising protein, fibre, and traditional ingredients (the programme works with Malayali food culture, not against it). 3) Exercise, structured movement programme including resistance training to preserve muscle during fat loss, plus HIIT and zone-2 cardio. 4) Skin preservation, protocols to prevent and treat "Ozempic face" (rapid fat-loss-related volume depletion in the face) using dermal fillers and skin-quality treatments at DermaVue.
Yes, rapid GLP-1-induced fat loss can cause visible volume depletion in the face, particularly the temples, cheeks, and nasolabial region. DermaVue addresses this proactively: dose titration is structured to avoid sudden weight loss; the skin-preservation pillar includes timely HA dermal-filler restoration, skin booster injections, and combination skin-quality treatments where needed. Being at a clinic that does both metabolic and aesthetic medicine is the operational advantage.
Initial consultation is ₹300 (same as any DermaVue dermatology consultation). Metabolic blood panel is separate, typically ₹3,500-5,500 depending on tests. Programme entry from ₹8,000/month including physician supervision + nutrition + exercise plan; medication cost is additional and depends on prescription (generic semaglutide from ₹325/week; brand Mounjaro/Ozempic from ₹13,125/month dose-dependent). All pricing is transparent before commitment, no hidden charges.
Dr. Rejeesh Menon (MBBS, MD Internal Medicine, US-licensed, WSU faculty, ACP Fellow) directs the SuperHuman programme across the DermaVue network. He is US-trained as an internist, the appropriate specialty for GLP-1 weight management, and brings the structured protocol approach that this class of medication requires. Branch physicians at the Kochi clinic handle follow-up reviews and skin-preservation work.
Contraindications include: pregnancy and lactation, personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN-2), history of pancreatitis, type 1 diabetes, severe gastrointestinal disease (including gastroparesis), and known hypersensitivity to GLP-1 analogues. The screening protocol catches these before any prescription. Most common side effects (nausea, transient GI symptoms) are managed with dose titration and dietary structure.
The active programme runs 12-18 months with planned maintenance phase after. Weight regain after stopping GLP-1 is well-documented in the literature, typically 1/3 to 2/3 of lost weight returns within a year of discontinuation if behaviour and nutrition do not change. The SuperHuman maintenance protocol is designed against this: structured tapering, ongoing nutrition coaching, resistance training to preserve metabolic rate, and lower-dose maintenance medication where clinically appropriate.
Yes, most SuperHuman patients are NOT walk-in distance from the Aluva clinic. The programme is built around monthly in-person physician reviews with WhatsApp + video check-ins between visits. Edappally is 12 minutes, Kakkanad is 12 minutes (NH-66), Kaloor is 16 minutes, Vyttila is 17 minutes, MG Road is 19 minutes or 35 minutes by direct metro. Many Kochi corporate professionals find Sunday slots (11 AM-5 PM) most workable for the monthly review.
Yes, PCOS with insulin resistance is one of the strongest indications for GLP-1 therapy in our Kochi cohort. Eligibility is assessed at BMI 23+ with metabolic comorbidity threshold. The programme combines GLP-1 (where indicated), inositol supplementation, structured nutrition for PCOS, and resistance training, plus dermatology support for the acne, hirsutism, and hair-thinning often associated with PCOS.
Eligibility, screening, and individual protocol decided before any prescription. No GLP-1 commitment required at consultation.